ELSEVIER

Diabetes Research and Clinical Practice 64 (2004) 231–233

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Author index of volume 64

Aban, I.B., see Baltazar, J.C. **64**, 107
Abe, Y., see Matsumoto, K. **64**, 225
Aida, K., see Komiyama, N. **64**, 11
Akahori, H., T. Takamura, T. Hayakawa, H. Ando, H. Yamashita, K.-i. Kobayashi, Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes–Weinstein monofilaments for evaluating diabetic sensory abnormality **64**, 153
Ancheta, C.A., see Baltazar, J.C. **64**, 107
Ando, H., see Akahori, H. **64**, 153
Andrès, E., see Vinzio, S. **64**, 181

Babazono, T., see Sakka, Y. **64**, 41
Baik, S.H., see Choi, K.M. **64**, 99
Baltazar, J.C., C.A. Ancheta, I.B. Aban, R.E. Fernando, M.M. Baquilod, Prevalence and correlates of diabetes mellitus and impaired glucose tolerance among adults in Luzon, Philippines **64**, 107
Baquilod, M.M., see Baltazar, J.C. **64**, 107
Birkeland, K.I., see Kølendorf, K. **64**, 33
Boned-Juliani, B., see Gimeno-Orna, J.A. **64**, 191
Boyages, S.C., see Wong, V.W. **64**, 85
Brimblecombe, J., see Maple-Brown, L.J. **64**, 77
Buono, P., see Valerio, G. **64**, 161

Chan, J.C.N., see Chan, W.B. **64**, 93
Chan, N.N., see Chan, W.B. **64**, 93
Chan, W.B., R.C.W. Ma, N.N. Chan, M.C.Y. Ng, Z.S.K. Lee, C.W.K. Lai, P.C.Y. Tong, W.Y. So, J.C.N. Chan, Increased leptin concentrations and lack of gender difference in Type 2 diabetic patients with nephropathy **64**, 93
Cheung, N. Wah, see Wong, V.W. **64**, 85
Chisholm, D., see Maple-Brown, L.J. **64**, 77
Choi, D.S., see Choi, K.M. **64**, 99
Choi, K.M., J. Lee, K.W. Lee, J.A. Seo, J.H. Oh, S.G. Kim, N.H. Kim, D.S. Choi, S.H. Baik, Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance **64**, 99
Connolly, V., see Pollock, R.D. **64**, 117
Critchley, J.A.J.H., see Neil Thomas, G. **64**, 123

Davidson, M.B., Letter to the Editor **64**, 229
del Puente, A., see Valerio, G. **64**, 161

Durrington, P.N., J. Tuomilehto, A. Hamann, D. Kallend, K. Smith, Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia **64**, 137

Eriksson, J., see Kølendorf, K. **64**, 33
Esposito, A., see Valerio, G. **64**, 161

Fernando, R.E., see Baltazar, J.C. **64**, 107
Franzese, A., see Valerio, G. **64**, 161
Fujii, M., see Miyatake, N. **64**, 173
Fukuda, H., see Nakanishi, N. **64**, 59
Fukushima, M., see Suzuki, H. **64**, 213

Gimeno-Orna, J.A., L.M. Lou-Arnal, B. Boned-Juliani, E. Molinero-Herguedas, Mild renal insufficiency as a cardiovascular risk factor in non-proteinuric type II diabetes **64**, 191
Goichot, B., see Vinzio, S. **64**, 181
Gomyo, M., N. Sakane, I. Kamae, S. Sato, K.-i. Suzuki, M. Tominaga, S. Kawazu, H. Yoshinaga, K. Tsushita, J. Sato, Y. Sato, S. Tsujii, T. Yoshida, Y. Seino, T. Usui, K. Nanjo, M. Hirata, K. Kotani, A. Hososako, Y. Kiyohara, H. Kuzuya, Effects of sex, age and BMI on screening tests for impaired glucose tolerance **64**, 129
Güntekın, R., see Özdırenç, M. **64**, 167

Hamann, A., see Durrington, P.N. **64**, 137
Hattori, Y., see Miyakoshi, K. **64**, 201
Hayakawa, T., see Akahori, H. **64**, 153
Hayakawa, T., see Kahara, T. **64**, 207
Hernaez-Ortega, M.C., E. Soto-Pedre, J.J.B. Martin, Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience **64**, 71
Hirata, M., see Gomyo, M. **64**, 129
Hong, A.W.L., see Neil Thomas, G. **64**, 123
Hosaka, Y., see Komiyama, N. **64**, 11
Hosokawa, M., see Suzuki, H. **64**, 213
Hososako, A., see Gomyo, M. **64**, 129
Hreidarsson, A.B., see Kølendorf, K. **64**, 33

Ikeda, M., see Suzuki, H. **64**, 213
Ishimoto, H., see Miyakoshi, K. **64**, 201
Ito, C., see Kataoka, M. **64**, 51
Iwamoto, Y., see Sakka, Y. **64**, 41
Iwamoto, Y., see Takaike, H. **64**, 27
Iwasaki, N., see Takaike, H. **64**, 27

doi:10.1016/S0168-8227(04)00095-6

Jeong, H.Y., H.Y. Jeong, C.D. Kim, p22phox-derived superoxide mediates enhanced proliferative capacity of diabetic vascular smooth muscle cells **64**, 1
Jeong, H.Y., see Jeong, H.Y. **64**, 1

Kahara, T., T. Hayakawa, Y. Nagai, A. Shimizu, T. Takamura, Gln27Glu polymorphism of the β2 adrenergic receptor gene in healthy Japanese men is associated with the change of fructosamine level caused by exercise **64**, 207
Kaku, K., F. Kawasaki, Y. Kanda, M. Matsuda, Retained capacity of glucose-mediated insulin secretion in patients with type 2 diabetes mellitus inversely correlates with the duration of diabetes **64**, 221
Kallend, D., see Durrington, P.N. **64**, 137
Kamae, I., see Gomyo, M. **64**, 129
Kamoi, K., M. Miyakoshi, R. Maruyama, A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion **64**, 19
Kanda, Y., see Kaku, K. **64**, 221
Kaneko, T., see Komiyama, N. **64**, 11
Kataoka, M., C. Ito, H. Sasaki, K. Yamane, N. Kohno, Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes **64**, 51
Kawasaki, F., see Kaku, K. **64**, 221
Kawasaki, Y., see Miyatake, N. **64**, 173
Kawazu, S., see Gomyo, M. **64**, 129
Kim, C.D., see Jeong, H.Y. **64**, 1
Kim, N.H., see Choi, K.M. **64**, 99
Kim, S.G., see Choi, K.M. **64**, 99
Kiyohara, Y., see Gomyo, M. **64**, 129
Kjellström, T., see Kølendorf, K. **64**, 33
Kølendorf, K., J. Eriksson, K.I. Birkeland, T. Kjellström, A.B. Hreidarsson, Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes **64**, 33
Kobayashi, K.-i., see Akahori, H. **64**, 153
Kobayashi, T., see Komiyama, N. **64**, 11
Koçak, G., see Özdırenç, M. **64**, 167
Kohno, N., see Kataoka, M. **64**, 51
Komiyama, N., T. Saito, Y. Hosaka, K. Aida, T. Kaneko, A. Sato, T. Onaya, T. Kobayashi, M. Tawata, Effects of a 4-week 70% high carbohydrate/15% low fat diet on glucose tolerance and on lipid profiles **64**, 11
Kotani, K., see Gomyo, M. **64**, 129
Kuzuya, H., see Gomyo, M. **64**, 129

Lai, C.W.K., see Chan, W.B. **64**, 93
Lam, C.W.K., see Neil Thomas, G. **64**, 123
Lau, E., see Neil Thomas, G. **64**, 123
Lee, J., see Choi, K.M. **64**, 99
Lee, K.W., see Choi, K.M. **64**, 99
Lee, Z.S.K., see Chan, W.B. **64**, 93
Li, W., see Nakanishi, N. **64**, 59
Lo, S.K., see Siu, S.C. **64**, 73
Lou-Arnal, L.M., see Gimeno-Orna, J.A. **64**, 191
Lu, H., see Sun, J. **64**, 185

Ma, R.C.W., see Chan, W.B. **64**, 93
Maple-Brown, L.J., J. Brimblecombe, D. Chisholm, K. O'Dea, Diabetes care and complications in a remote primary health care setting **64**, 77
Martin, J.J.B., see Hernaez-Ortega, M.C. **64**, 71
Maruyama, R., see Kamoi, K. **64**, 19
Mastidoro, L., see Valerio, G. **64**, 161
Matsuda, M., see Kaku, K. **64**, 221
Matsumoto, K., Y. Sera, Y. Abe, T. Tominaga, Y. Yeki, S. Miyake, Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes **64**, 225
Matsumoto, T., see Miyakoshi, K. **64**, 201
Matsuo, Y., see Nakanishi, N. **64**, 59
Matsuura, T., see Suzuki, H. **64**, 213
Minegishi, K., see Miyakoshi, K. **64**, 201
Miyake, S., see Matsumoto, K. **64**, 225
Miyakoshi, K., M. Tanaka, T. Matsumoto, Y. Hattori, K. Ueno, T. Teranishi, K. Minegishi, H. Ishimoto, A. Shimada, Y. Yoshimura, Hypertensive disorders in Japanese women with gestational glucose intolerance **64**, 201
Miyakoshi, M., see Kamoi, K. **64**, 19
Miyatake, N., S. Takanami, Y. Kawasaki, M. Fujii, Relationship between visceral fat accumulation and physical fitness in Japanese women **64**, 173
Molinero-Herguedas, E., see Gimeno-Orna, J.A. **64**, 191
Moretto, E., see Valerio, G. **64**, 161
Mozzillo, E., see Valerio, G. **64**, 161

Nagai, Y., see Kahara, T. **64**, 207
Nakai, Y., see Suzuki, H. **64**, 213
Nakanishi, N., T. Takatorige, H. Fukuda, K. Shirai, W. Li, M. Okamoto, H. Yoshida, Y. Matsuo, K. Suzuki, K. Tatara, Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men **64**, 59
Nanjo, K., see Gomyo, M. **64**, 129
Neil Thomas, G., A.W.L. Hong, B. Tomlinson, C.W.K. Lam, J.A.J.H. Critchley, J.E. Sanderson, J. Woo, E. Lau, Increasing insulin resistance contributes to worsening glycaemic and lipid profiles in older Chinese subjects **64**, 123
Ng, M.C.Y., see Chan, W.B. **64**, 93

O'Dea, K., see Maple-Brown, L.J. **64**, 77
Oh, J.H., see Choi, K.M. **64**, 99
Okamoto, M., see Nakanishi, N. **64**, 59
Onaya, T., see Komiyama, N. **64**, 11
Özdırenç, M., G. Koçak, R. Güntekın, The acute effects of in-patient physiotherapy program on functional capacity in type II diabetes mellitus **64**, 167

Park, K., see Wong, V.W. **64**, 85
Perrin, A.-E., see Vinzio, S. **64**, 181
Pollock, R.D., N.C. Unwin, V. Connolly, Knowledge and practice of foot care in people with diabetes **64**, 117

Ross, D.L., see Wong, V.W. **64**, 85

Saito, T., see Komiyama, N. **64**, 11

Sakane, N., see Gomyo, M. **64**, 129
Sakka, Y., T. Babazono, A. Sato, N. Ujihara, Y. Iwamoto, ACE gene polymorphism, left ventricular geometry, and mortality in diabetic patients with end-stage renal disease **64**, 41
Sanderson, J.E., see Neil Thomas, G. **64**, 123
Sasaki, H., see Kataoka, M. **64**, 51
Sato, A., see Komiyama, N. **64**, 11
Sato, A., see Sakka, Y. **64**, 41
Sato, J., see Gomyo, M. **64**, 129
Sato, S., see Gomyo, M. **64**, 129
Sato, Y., see Gomyo, M. **64**, 129
Schlienger, J.-L., see Vinzio, S. **64**, 181
Seino, Y., see Gomyo, M. **64**, 129
Seino, Y., see Suzuki, H. **64**, 213
Seo, J.A., see Choi, K.M. **64**, 99
Sera, Y., see Matsumoto, K. **64**, 225
Shimada, A., see Miyakoshi, K. **64**, 201
Shimizu, A., see Kahara, T. **64**, 207
Shirai, K., see Nakanishi, N. **64**, 59
Siu, S.C., S.K. Lo, K.W. Wong, Outcomes of diabetes patients attending a hospital diabetes clinic **64**, 73
Smith, K., see Durrington, P.N. **64**, 137
So, W.Y., see Chan, W.B. **64**, 93
Soto-Pedre, E., see Hernaez-Ortega, M.C. **64**, 71
Sun, J., Y. Xu, Y. Zhu, H. Lu, Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients **64**, 185
Suzuki, H., M. Fukushima, M. Usami, M. Ikeda, A. Taniguchi, Y. Nakai, T. Matsuura, K. Yasuda, M. Hosokawa, Y. Seino, Y. Yamada, IGT with fasting hyperglycemia is more strongly associated with microalbuminuria than IGT without fasting hyperglycemia **64**, 213
Suzuki, K., see Nakanishi, N. **64**, 59
Suzuki, K.-i., see Gomyo, M. **64**, 129

Takaike, H., Y. Uchigata, N. Iwasaki, Y. Iwamoto, Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus **64**, 27
Takamura, T., see Akahori, H. **64**, 153
Takamura, T., see Kahara, T. **64**, 207
Takanami, S., see Miyatake, N. **64**, 173
Takatorige, T., see Nakanishi, N. **64**, 59
Tanaka, M., see Miyakoshi, K. **64**, 201
Taniguchi, A., see Suzuki, H. **64**, 213
Tatara, K., see Nakanishi, N. **64**, 59
Tawata, M., see Komiyama, N. **64**, 11
Teranishi, T., see Miyakoshi, K. **64**, 201
Tominaga, M., see Gomyo, M. **64**, 129
Tominaga, T., see Matsumoto, K. **64**, 225
Tomlinson, B., see Neil Thomas, G. **64**, 123
Tong, P.C.Y., see Chan, W.B. **64**, 93
Tsujii, S., see Gomyo, M. **64**, 129
Tsushita, K., see Gomyo, M. **64**, 129
Tuomilehto, J., see Durrington, P.N. **64**, 137

Uchigata, Y., see Takaike, H. **64**, 27
Ueno, K., see Miyakoshi, K. **64**, 201
Ujihara, N., see Sakka, Y. **64**, 41
Unwin, N.C., see Pollock, R.D. **64**, 117
Usami, M., see Suzuki, H. **64**, 213
Usui, T., see Gomyo, M. **64**, 129

Valerio, G., A. del Puente, P. Buono, A. Esposito, M. Zanatta, E. Mozzillo, E. Moretto, L. Mastidoro, A. Franzese, Quantitative ultrasound of proximal phalanxes in patients with type 1 diabetes mellitus **64**, 161
Vinzio, S., E. Andrès, A.-E. Perrin, J.-L. Schlienger, B. Goichot, Glibenclamide-induced acute haemolytic anaemia revealing a G6PD-deficiency **64**, 181

Wong, K.W., see Siu, S.C. **64**, 73
Wong, V.W., D.L. Ross, K. Park, S.C. Boyages, N. Wah Cheung, Hyperglycemia: still an important predictor of adverse outcomes following AMI in the reperfusion era **64**, 85
Woo, J., see Thomas, G. Neil **64**, 123

Xu, Y., see Sun, J. **64**, 185

Yamada, Y., see Suzuki, H. **64**, 213
Yamane, K., see Kataoka, M. **64**, 51
Yamashita, H., see Akahori, H. **64**, 153
Yasuda, K., see Suzuki, H. **64**, 213
Yeki, Y., see Matsumoto, K. **64**, 225
Yoshida, H., see Nakanishi, N. **64**, 59
Yoshida, T., see Gomyo, M. **64**, 129
Yoshimura, Y., see Miyakoshi, K. **64**, 201
Yoshinaga, H., see Gomyo, M. **64**, 129

Zanatta, M., see Valerio, G. **64**, 161
Zhu, Y., see Sun, J. **64**, 185

ELSEVIER

Diabetes Research and Clinical Practice 64 (2004) 235–239

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

Subject index of volume 64

β2 adrenergic receptor; Gln27Glu; Polymorphism; Fructosamine; Exercise **64**, 207

Aboriginal; Type 2 diabetes; Albuminuria; Peripheral neuropathy; Retinopathy; Primary health care **64**, 77

Acute haemolytic anaemia; Diabetes mellitus; Glucose-6-phosphate dehydrogenase deficiency; Glibenclamide; Oxidative stress **64**, 181

Acute myocardial infarction; Hyperglycemia; Mortality; Reperfusion; Diabetes mellitus **64**, 85

Acute-phase protein; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Albuminuria; Cardiovascular disease; Insulin sensitivity; Dyslipidaemia; Metabolic syndrome; Obesity **64**, 123

Albuminuria; Type 2 diabetes; Peripheral neuropathy; Retinopathy; Aboriginal; Primary health care **64**, 77

ALT; Type 1 diabetes; Diabetic ketoacidosis; Fatty liver; AST **64**, 27

Angiotensin converting enzyme (ACE) gene polymorphism; Diabetic nephropathy; End-stage renal disease; Left ventricular hypertrophy; Relative wall thickness **64**, 41

Anthropometric parameters; Visceral fat area; Computed tomography; Ventilatory threshold; Weight bearing index **64**, 173

AST; Type 1 diabetes; Diabetic ketoacidosis; Fatty liver; ALT **64**, 27

Atherosclerosis; Metformin; Type 2 diabetes mellitus; Carotid artery **64**, 225

BMI; High carbohydrate/low fat diet; Glucose tolerance; HDL–Cholesterol; Triglyceride; Free fatty acids **64**, 11

Bone quality; Children; Calcium intake; Glycated hemoglobin; Quantitative ultrasound; Type 1 diabetes mellitus **64**, 161

C-reactive protein; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Calcium intake; Bone quality; Children; Glycated hemoglobin; Quantitative ultrasound; Type 1 diabetes mellitus **64**, 161

Cardiac sudden death; Type 2 diabetes mellitus; Heart rate variability **64**, 51

Cardiovascular disease; Albuminuria; Insulin sensitivity; Dyslipidaemia; Metabolic syndrome; Obesity **64**, 123

Cardiovascular disease; Type 2 diabetes; Incidence; Metabolic syndrome; Japanese men **64**, 59

Cardiovascular; Mild renal insufficiency; Mortality; Type II diabetes **64**, 191

Carotid artery; Metformin; Type 2 diabetes mellitus; Atherosclerosis **64**, 225

Children; Bone quality; Calcium intake; Glycated hemoglobin; Quantitative ultrasound; Type 1 diabetes mellitus **64**, 161

Chinese; Leptin; Diabetic nephropathy; Gender **64**, 93

Combination drug therapy; Rosuvastatin; Fenofibrate; Type 2 diabetes mellitus; Familial combined hyperlipidaemia **64**, 137

doi:10.1016/S0168-8227(04)00096-8

Computed tomography; Visceral fat area; Anthropometric parameters; Ventilatory threshold; Weight bearing index **64**, 173

Cross-sectional survey; Diabetes mellitus; Foot ulcer; Foot care; High risk **64**, 117

CSII; QOL; MDI; Insulin lispro **64**, 19

Cystoid macular edema; Diabetes mellitus; Diabetic retinopathy; Somatostatin **64**, 71

Cytokine; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Systemic inflammation **64**, 99

Diabetes mellitus; Cross-sectional survey; Foot ulcer; Foot care; High risk **64**, 117

Diabetes mellitus; Diabetic retinopathy; Cystoid macular edema; Somatostatin **64**, 71

Diabetes mellitus; Glucose-6-phosphate dehydrogenase deficiency; Glibenclamide; Acute haemolytic anaemia; Oxidative stress **64**, 181

Diabetes mellitus; Hyperglycemia; Acute myocardial infarction; Mortality; Reperfusion **64**, 85

Diabetes mellitus; Impaired glucose tolerance; Oral glucose tolerance test; Prevalence; Risk factors **64**, 107

Diabetes; Exercise training; Physiotherapy **64**, 167

Diabetes; NAD(P)H oxidase; Superoxide; VSMC proliferation **64**, 1

Diabetic ketoacidosis; Type 1 diabetes; Fatty liver; AST; ALT **64**, 27

Diabetic nephropathy; End-stage renal disease; Angiotensin converting enzyme (ACE) gene polymorphism; Left ventricular hypertrophy; Relative wall thickness **64**, 41

Diabetic nephropathy; Genetics; Methylenetetrahydrofolate reductase; Type 2 diabetes mellitus **64**, 185

Diabetic nephropathy; Leptin; Chinese; Gender **64**, 93

Diabetic peripheral neuropathy; Lipo-PGE1; Semmes–Weinstein monofilaments **64**, 153

Diabetic retinopathy; Diabetes mellitus; Cystoid macular edema; Somatostatin **64**, 71

Dose titration; Repaglinide; Type 2 diabetes **64**, 33

Dyslipidaemia; Albuminuria; Cardiovascular disease; Insulin sensitivity; Metabolic syndrome; Obesity **64**, 123

End-stage renal disease; Diabetic nephropathy; Angiotensin converting enzyme (ACE) gene polymorphism; Left ventricular hypertrophy; Relative wall thickness **64**, 41

Exercise training; Diabetes; Physiotherapy **64**, 167

Exercise; β2 adrenergic receptor; Gln27Glu; Polymorphism; Fructosamine **64**, 207

Familial combined hyperlipidaemia; Rosuvastatin; Fenofibrate; Type 2 diabetes mellitus; Combination drug therapy **64**, 137

Fasting hyperglycemia; Microalbuminuria; Impaired glucose tolerance; Type 2 diabetes; Insulin resistance **64**, 213

Fatty liver; Type 1 diabetes; Diabetic ketoacidosis; AST; ALT **64**, 27

Fenofibrate; Rosuvastatin; Type 2 diabetes mellitus; Familial combined hyperlipidaemia; Combination drug therapy **64**, 137

Foot care; Diabetes mellitus; Cross-sectional survey; Foot ulcer; High risk **64**, 117

Foot ulcer; Diabetes mellitus; Cross-sectional survey; Foot care; High risk **64**, 117

FPG; IGT; Screening; ROC curve; Prevention **64**, 129

Free fatty acids; High carbohydrate/low fat diet; Glucose tolerance; HDL–Cholesterol; Triglyceride; BMI **64**, 11

Fructosamine; β2 adrenergic receptor; Gln27Glu; Polymorphism; Exercise **64**, 207

Gender; Leptin; Diabetic nephropathy; Chinese **64**, 93

Genetics; Methylenetetrahydrofolate reductase; Type 2 diabetes mellitus; Diabetic nephropathy **64**, 185

Gestational glucose intolerance; Gestational hypertension; Preeclampsia; Japanese population **64**, 201

Gestational hypertension; Gestational glucose intolerance; Preeclampsia; Japanese population **64**, 201

Glibenclamide; Diabetes mellitus; Glucose-6-phosphate dehydrogenase deficiency; Acute haemolytic anaemia; Oxidative stress **64**, 181

Gln27Glu; β2 adrenergic receptor; Polymorphism; Fructosamine; Exercise **64**, 207

Glucose tolerance; High carbohydrate/low fat diet; HDL–Cholesterol; Triglyceride; Free fatty acids; BMI **64**, 11

Glucose toxicity; Type 2 diabetes; Insulin secretion **64**, 221

Glucose-6-phosphate dehydrogenase deficiency; Diabetes mellitus; Glibenclamide; Acute haemolytic anaemia; Oxidative stress **64**, 181

Glycated hemoglobin; Bone quality; Children; Calcium intake; Quantitative ultrasound; Type 1 diabetes mellitus **64**, 161

HDL–Cholesterol; High carbohydrate/low fat diet; Glucose tolerance; Triglyceride; Free fatty acids; BMI **64**, 11

Heart rate variability; Type 2 diabetes mellitus; Cardiac sudden death **64**, 51

High carbohydrate/low fat diet; Glucose tolerance; HDL–Cholesterol; Triglyceride; Free fatty acids; BMI **64**, 11

High risk; Diabetes mellitus; Cross-sectional survey; Foot ulcer; Foot care **64**, 117

Hyperglycemia; Acute myocardial infarction; Mortality; Reperfusion; Diabetes mellitus **64**, 85

IGT; Screening; FPG; ROC curve; Prevention **64**, 129

Impaired glucose tolerance; Diabetes mellitus; Oral glucose tolerance test; Prevalence; Risk factors **64**, 107

Impaired glucose tolerance; Microalbuminuria; Fasting hyperglycemia; Type 2 diabetes; Insulin resistance **64**, 213

Impaired glucose tolerance; Type 2 diabetes; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Incidence; Cardiovascular disease; Type 2 diabetes; Metabolic syndrome; Japanese men **64**, 59

Insulin lispro; QOL; CSII; MDI **64**, 19

Insulin resistance; Microalbuminuria; Impaired glucose tolerance; Fasting hyperglycemia; Type 2 diabetes **64**, 213

Insulin resistance; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Cytokine; Systemic inflammation **64**, 99

Insulin secretion; Type 2 diabetes; Glucose toxicity **64**, 221

Insulin sensitivity; Albuminuria; Cardiovascular disease; Dyslipidaemia; Metabolic syndrome; Obesity **64**, 123

Interleukin 6; Type 2 diabetes; Impaired glucose tolerance; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Japanese men; Cardiovascular disease; Type 2 diabetes; Incidence; Metabolic syndrome **64**, 59

Japanese population; Gestational glucose intolerance; Gestational hypertension; Preeclampsia **64**, 201

Left ventricular hypertrophy; Diabetic nephropathy; End-stage renal disease; Angiotensin converting enzyme (ACE) gene polymorphism; Relative wall thickness **64**, 41

Leptin; Diabetic nephropathy; Chinese; Gender **64**, 93

Lipo-PGE1; Diabetic peripheral neuropathy; Semmes–Weinstein monofilaments **64**, 153

MDI; QOL; CSII; Insulin lispro **64**, 19

Metabolic syndrome; Albuminuria; Cardiovascular disease; Insulin sensitivity; Dyslipidaemia; Obesity **64**, 123

Metabolic syndrome; Cardiovascular disease; Type 2 diabetes; Incidence; Japanese men **64**, 59

Metabolic syndrome; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Metformin; Type 2 diabetes mellitus; Carotid artery; Atherosclerosis **64**, 225

Methylenetetrahydrofolate reductase; Genetics; Type 2 diabetes mellitus; Diabetic nephropathy **64**, 185

Microalbuminuria; Impaired glucose tolerance; Fasting hyperglycemia; Type 2 diabetes; Insulin resistance **64**, 213

Mild renal insufficiency; Mortality; Cardiovascular; Type II diabetes **64**, 191

Mortality; Hyperglycemia; Acute myocardial infarction; Reperfusion; Diabetes mellitus **64**, 85

Mortality; Mild renal insufficiency; Cardiovascular; Type II diabetes **64**, 191

NAD(P)H oxidase; Diabetes; Superoxide; VSMC proliferation **64**, 1

Obesity; Albuminuria; Cardiovascular disease; Insulin sensitivity; Dyslipidaemia; Metabolic syndrome **64**, 123

Oral glucose tolerance test; Diabetes mellitus; Impaired glucose tolerance; Prevalence; Risk factors **64**, 107

Oxidative stress; Diabetes mellitus; Glucose-6-phosphate dehydrogenase deficiency; Glibenclamide; Acute haemolytic anaemia **64**, 181

Peripheral neuropathy; Type 2 diabetes; Albuminuria; Retinopathy; Aboriginal; Primary health care **64**, 77

Physiotherapy; Diabetes; Exercise training **64**, 167

Polymorphism; β2 adrenergic receptor; Gln27Glu; Fructosamine; Exercise **64**, 207

Preeclampsia; Gestational glucose intolerance; Gestational hypertension; Japanese population **64**, 201

Prevalence; Diabetes mellitus; Impaired glucose tolerance; Oral glucose tolerance test; Risk factors **64**, 107

Prevention; IGT; Screening; FPG; ROC curve **64**, 129

Primary health care; Type 2 diabetes; Albuminuria; Peripheral neuropathy; Retinopathy; Aboriginal **64**, 77

QOL; CSII; MDI; Insulin lispro **64**, 19

Quantitative ultrasound; Bone quality; Children; Calcium intake; Glycated hemoglobin; Type 1 diabetes mellitus **64**, 161

Relative wall thickness; Diabetic nephropathy; End-stage renal disease; Angiotensin converting enzyme (ACE) gene polymorphism; Left ventricular hypertrophy **64**, 41

Repaglinide; Dose titration; Type 2 diabetes **64**, 33

Reperfusion; Hyperglycemia; Acute myocardial infarction; Mortality; Diabetes mellitus **64**, 85

Retinopathy; Type 2 diabetes; Albuminuria; Peripheral neuropathy; Aboriginal; Primary health care **64**, 77

Risk factors; Diabetes mellitus; Impaired glucose tolerance; Oral glucose tolerance test; Prevalence **64**, 107

ROC curve; IGT; Screening; FPG; Prevention **64**, 129

Rosuvastatin; Fenofibrate; Type 2 diabetes mellitus; Familial combined hyperlipidaemia; Combination drug therapy **64**, 137

Screening; IGT; FPG; ROC curve; Prevention **64**, 129

Semmes–Weinstein monofilaments; Diabetic peripheral neuropathy; Lipo-PGE1 **64**, 153

Somatostatin; Diabetes mellitus; Diabetic retinopathy; Cystoid macular edema **64**, 71

Superoxide; Diabetes; NAD(P)H oxidase; VSMC proliferation **64**, 1

Systemic inflammation; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine **64**, 99

Triglyceride; High carbohydrate/low fat diet; Glucose tolerance; HDL–Cholesterol; Free fatty acids; BMI **64**, 11

Tumor necrosis factor α; Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Type 1 diabetes mellitus; Bone quality; Children; Calcium intake; Glycated hemoglobin; Quantitative ultrasound **64**, 161

Type 1 diabetes; Diabetic ketoacidosis; Fatty liver; AST; ALT **64**, 27

Type 2 diabetes mellitus; Genetics; Methylenetetrahydrofolate reductase; Diabetic nephropathy **64**, 185

Type 2 diabetes mellitus; Heart rate variability; Cardiac sudden death **64**, 51

Type 2 diabetes mellitus; Metformin; Carotid artery; Atherosclerosis **64**, 225

Type 2 diabetes mellitus; Rosuvastatin; Fenofibrate; Familial combined hyperlipidaemia; Combination drug therapy **64**, 137

Type 2 diabetes; Albuminuria; Peripheral neuropathy; Retinopathy; Aboriginal; Primary health care **64**, 77

Type 2 diabetes; Cardiovascular disease; Incidence; Metabolic syndrome; Japanese men **64**, 59

Type 2 diabetes; Dose titration; Repaglinide **64**, 33

Type 2 diabetes; Impaired glucose tolerance; Interleukin 6; Tumor necrosis factor α; C-reactive protein; Acute-phase protein; Metabolic syndrome; Insulin resistance; Cytokine; Systemic inflammation **64**, 99

Type 2 diabetes; Insulin secretion; Glucose toxicity **64**, 221

Type 2 diabetes; Microalbuminuria; Impaired glucose tolerance; Fasting hyperglycemia; Insulin resistance **64**, 213

Type II diabetes; Mild renal insufficiency; Mortality; Cardiovascular **64**, 191

Ventilatory threshold; Visceral fat area; Anthropometric parameters; Computed tomography; Weight bearing index **64**, 173

Visceral fat area; Anthropometric parameters; Computed tomography; Ventilatory threshold; Weight bearing index **64**, 173

VSMC proliferation; Diabetes; NAD(P)H oxidase; Superoxide **64**, 1

Weight bearing index; Visceral fat area; Anthropometric parameters; Computed tomography; Ventilatory threshold **64**, 173